Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

AXL receptor tyrosine kinase/cMET inhibitor BPI-9016M

An orally available inhibitor of the AXL receptor tyrosine kinase (AXL; UFO) and the receptor tyrosine kinase c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Upon administration, AXL receptor tyrosine kinase/cMET inhibitor BPI-9016M, binds to both AXL and cMet, thereby disrupting both AXL- and c-Met-mediated signaling pathways. Altogether, this agent inhibits growth in AXL and cMet-overexpressing tumor cells. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, and cMet, both overexpressed by many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AXL receptor tyrosine kinase/c-MET inhibitor BPI-9016M
AXL/cMET inhibitor BPI-9016M
Code name:BPI 9016
BPI-9016
BPI-9016M
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search